Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Systemic Inflammatory Response Syndrome | 7 | 2022 | 34 | 1.100 |
Why?
|
| Respiratory Insufficiency | 2 | 2016 | 76 | 1.010 |
Why?
|
| Pyridones | 1 | 2022 | 40 | 0.870 |
Why?
|
| Intensive Care Units, Pediatric | 5 | 2021 | 101 | 0.850 |
Why?
|
| Venous Thromboembolism | 1 | 2022 | 116 | 0.780 |
Why?
|
| Hospitalization | 12 | 2023 | 977 | 0.720 |
Why?
|
| Child | 26 | 2023 | 6400 | 0.690 |
Why?
|
| Quality Improvement | 2 | 2020 | 413 | 0.630 |
Why?
|
| Critical Care | 3 | 2022 | 263 | 0.620 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2018 | 503 | 0.580 |
Why?
|
| Colonic Diseases | 2 | 2008 | 36 | 0.560 |
Why?
|
| Emergencies | 1 | 2016 | 107 | 0.540 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 72 | 0.530 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2015 | 16 | 0.520 |
Why?
|
| Heart Arrest | 1 | 2016 | 113 | 0.520 |
Why?
|
| Naloxone | 1 | 2015 | 56 | 0.520 |
Why?
|
| Buprenorphine | 1 | 2015 | 67 | 0.490 |
Why?
|
| Practice Guidelines as Topic | 3 | 2020 | 772 | 0.470 |
Why?
|
| Infant | 10 | 2022 | 2891 | 0.460 |
Why?
|
| Child, Preschool | 11 | 2022 | 3185 | 0.440 |
Why?
|
| Cystic Fibrosis | 2 | 2008 | 283 | 0.430 |
Why?
|
| Superior Vena Cava Syndrome | 1 | 2011 | 15 | 0.420 |
Why?
|
| Pediatrics | 2 | 2022 | 341 | 0.400 |
Why?
|
| Nervous System Diseases | 2 | 2023 | 142 | 0.390 |
Why?
|
| Quality Assurance, Health Care | 2 | 2013 | 177 | 0.380 |
Why?
|
| Humans | 39 | 2023 | 68525 | 0.380 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 19 | 0.370 |
Why?
|
| Thrombosis | 1 | 2011 | 218 | 0.370 |
Why?
|
| Vascular Surgical Procedures | 1 | 2011 | 168 | 0.370 |
Why?
|
| Medical Errors | 2 | 2013 | 80 | 0.320 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2009 | 88 | 0.310 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 130 | 0.310 |
Why?
|
| Adolescent | 14 | 2023 | 8903 | 0.300 |
Why?
|
| Oximetry | 1 | 2007 | 29 | 0.300 |
Why?
|
| United States | 13 | 2023 | 7335 | 0.280 |
Why?
|
| Male | 19 | 2023 | 37281 | 0.260 |
Why?
|
| Female | 19 | 2023 | 38015 | 0.260 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2022 | 92 | 0.250 |
Why?
|
| Treatment Refusal | 1 | 2004 | 40 | 0.250 |
Why?
|
| Critical Illness | 4 | 2022 | 191 | 0.240 |
Why?
|
| Connective Tissue Diseases | 1 | 2023 | 18 | 0.230 |
Why?
|
| Guillain-Barre Syndrome | 1 | 2023 | 8 | 0.230 |
Why?
|
| Immunity, Maternally-Acquired | 1 | 2022 | 4 | 0.220 |
Why?
|
| Child, Hospitalized | 1 | 2022 | 16 | 0.210 |
Why?
|
| Influenza, Human | 1 | 2023 | 79 | 0.210 |
Why?
|
| Hospitalists | 1 | 2022 | 21 | 0.210 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2021 | 277 | 0.210 |
Why?
|
| Aftercare | 2 | 2022 | 114 | 0.200 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2021 | 52 | 0.200 |
Why?
|
| Education, Continuing | 1 | 2020 | 28 | 0.190 |
Why?
|
| Education, Distance | 1 | 2021 | 34 | 0.190 |
Why?
|
| Biological Products | 1 | 2021 | 78 | 0.180 |
Why?
|
| Glucocorticoids | 1 | 2021 | 222 | 0.180 |
Why?
|
| Hospitals, Pediatric | 4 | 2022 | 114 | 0.170 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 234 | 0.170 |
Why?
|
| Antiviral Agents | 1 | 2021 | 211 | 0.170 |
Why?
|
| Atracurium | 1 | 2018 | 3 | 0.170 |
Why?
|
| Vecuronium Bromide | 1 | 2018 | 4 | 0.170 |
Why?
|
| Dexmedetomidine | 1 | 2018 | 13 | 0.160 |
Why?
|
| Fentanyl | 1 | 2018 | 26 | 0.160 |
Why?
|
| Midazolam | 1 | 2018 | 46 | 0.160 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 215 | 0.160 |
Why?
|
| Morphine | 1 | 2018 | 76 | 0.160 |
Why?
|
| Case-Control Studies | 4 | 2022 | 1548 | 0.160 |
Why?
|
| Patient Acuity | 3 | 2022 | 17 | 0.160 |
Why?
|
| Sepsis | 1 | 2020 | 233 | 0.160 |
Why?
|
| Infusions, Intravenous | 1 | 2018 | 334 | 0.150 |
Why?
|
| Vaccination | 3 | 2023 | 182 | 0.150 |
Why?
|
| Cell Phone | 1 | 2017 | 43 | 0.140 |
Why?
|
| Accidents, Home | 1 | 2015 | 9 | 0.130 |
Why?
|
| Biological Availability | 1 | 2015 | 79 | 0.130 |
Why?
|
| Disorders of Excessive Somnolence | 1 | 2015 | 28 | 0.130 |
Why?
|
| Graft Rejection | 1 | 2018 | 458 | 0.130 |
Why?
|
| Mental Health | 1 | 2017 | 278 | 0.120 |
Why?
|
| Pandemics | 3 | 2023 | 346 | 0.120 |
Why?
|
| Treatment Outcome | 4 | 2021 | 7028 | 0.120 |
Why?
|
| Narcotic Antagonists | 1 | 2015 | 184 | 0.120 |
Why?
|
| Emergency Responders | 1 | 2013 | 9 | 0.110 |
Why?
|
| Kidney | 1 | 2018 | 945 | 0.110 |
Why?
|
| Health Behavior | 1 | 2017 | 458 | 0.110 |
Why?
|
| Inservice Training | 1 | 2013 | 68 | 0.110 |
Why?
|
| Patient Simulation | 1 | 2013 | 64 | 0.110 |
Why?
|
| Safety Management | 1 | 2013 | 73 | 0.110 |
Why?
|
| Pseudomonas | 1 | 2011 | 8 | 0.100 |
Why?
|
| Pregnancy | 3 | 2022 | 2331 | 0.100 |
Why?
|
| Antibodies, Viral | 2 | 2022 | 110 | 0.100 |
Why?
|
| Pseudomonas Infections | 1 | 2011 | 83 | 0.100 |
Why?
|
| Patient Care Team | 1 | 2013 | 311 | 0.100 |
Why?
|
| Infant, Newborn | 3 | 2022 | 2453 | 0.090 |
Why?
|
| Kidney Transplantation | 1 | 2018 | 839 | 0.090 |
Why?
|
| Stroke | 1 | 2023 | 2161 | 0.090 |
Why?
|
| Intensive Care Units | 2 | 2022 | 344 | 0.090 |
Why?
|
| Analgesics, Opioid | 1 | 2015 | 498 | 0.090 |
Why?
|
| Patient Discharge | 2 | 2022 | 294 | 0.090 |
Why?
|
| Quality Control | 1 | 2009 | 81 | 0.080 |
Why?
|
| Anticoagulants | 1 | 2011 | 356 | 0.080 |
Why?
|
| Colectomy | 1 | 2008 | 64 | 0.080 |
Why?
|
| Carbon Monoxide Poisoning | 1 | 2007 | 1 | 0.080 |
Why?
|
| Sulfhemoglobinemia | 1 | 2007 | 1 | 0.080 |
Why?
|
| Methemoglobinemia | 1 | 2007 | 6 | 0.080 |
Why?
|
| Disease Management | 1 | 2009 | 248 | 0.070 |
Why?
|
| Gallbladder | 2 | 1995 | 15 | 0.070 |
Why?
|
| Clinical Protocols | 1 | 2007 | 172 | 0.070 |
Why?
|
| Young Adult | 3 | 2022 | 5708 | 0.070 |
Why?
|
| Empyema, Pleural | 1 | 2005 | 13 | 0.070 |
Why?
|
| Methicillin Resistance | 1 | 2005 | 45 | 0.070 |
Why?
|
| Biomarkers | 2 | 2021 | 1593 | 0.070 |
Why?
|
| Obesity | 2 | 2023 | 1074 | 0.070 |
Why?
|
| Pancrelipase | 1 | 2004 | 2 | 0.060 |
Why?
|
| Ultrasonic Therapy | 1 | 1984 | 19 | 0.060 |
Why?
|
| Cholelithiasis | 1 | 1984 | 66 | 0.060 |
Why?
|
| Staphylococcus aureus | 1 | 2005 | 175 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2009 | 1753 | 0.060 |
Why?
|
| Gastrointestinal Agents | 1 | 2004 | 51 | 0.060 |
Why?
|
| Staphylococcal Infections | 1 | 2005 | 156 | 0.060 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 2 | 1 | 2023 | 1 | 0.060 |
Why?
|
| Receptor, Notch1 | 1 | 2023 | 11 | 0.060 |
Why?
|
| Neutralization Tests | 1 | 2022 | 19 | 0.050 |
Why?
|
| Adult | 3 | 2022 | 21375 | 0.050 |
Why?
|
| Spike Glycoprotein, Coronavirus | 1 | 2022 | 20 | 0.050 |
Why?
|
| Immunization, Passive | 1 | 2022 | 24 | 0.050 |
Why?
|
| Seroepidemiologic Studies | 1 | 2022 | 41 | 0.050 |
Why?
|
| Viral Envelope Proteins | 1 | 2022 | 43 | 0.050 |
Why?
|
| Immunization, Secondary | 1 | 2022 | 17 | 0.050 |
Why?
|
| Life Support Care | 1 | 2022 | 12 | 0.050 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2022 | 35 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 190 | 0.050 |
Why?
|
| Public Health Surveillance | 1 | 2021 | 18 | 0.050 |
Why?
|
| Pediatric Dentistry | 1 | 2021 | 3 | 0.050 |
Why?
|
| Shock | 1 | 2021 | 28 | 0.050 |
Why?
|
| Glycerides | 1 | 1981 | 18 | 0.050 |
Why?
|
| Immunomodulation | 1 | 2021 | 35 | 0.050 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2023 | 199 | 0.050 |
Why?
|
| Inpatients | 1 | 2023 | 208 | 0.050 |
Why?
|
| Propensity Score | 1 | 2021 | 116 | 0.050 |
Why?
|
| Gallstones | 1 | 1981 | 58 | 0.050 |
Why?
|
| Mothers | 1 | 2022 | 172 | 0.050 |
Why?
|
| Catheterization | 1 | 1981 | 209 | 0.050 |
Why?
|
| Membrane Glycoproteins | 1 | 2022 | 370 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 648 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2022 | 481 | 0.040 |
Why?
|
| Electronic Health Records | 1 | 2023 | 374 | 0.040 |
Why?
|
| Health Personnel | 1 | 2022 | 286 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2021 | 737 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 951 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2023 | 1663 | 0.040 |
Why?
|
| Guideline Adherence | 1 | 2020 | 284 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2021 | 586 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2023 | 7264 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1139 | 0.040 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 445 | 0.040 |
Why?
|
| Logistic Models | 1 | 2021 | 1419 | 0.040 |
Why?
|
| Ownership | 1 | 2017 | 18 | 0.040 |
Why?
|
| Family Characteristics | 1 | 2017 | 44 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 1030 | 0.040 |
Why?
|
| Patient Safety | 1 | 2018 | 202 | 0.030 |
Why?
|
| Biopsy | 1 | 2018 | 539 | 0.030 |
Why?
|
| Age Factors | 1 | 2021 | 1860 | 0.030 |
Why?
|
| Cholecystitis | 1 | 1995 | 12 | 0.030 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 1995 | 21 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2021 | 2356 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2022 | 3702 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 955 | 0.030 |
Why?
|
| Rural Population | 1 | 2017 | 397 | 0.030 |
Why?
|
| Coronary Care Units | 1 | 2013 | 12 | 0.030 |
Why?
|
| Ohio | 1 | 2013 | 64 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 2013 | 47 | 0.030 |
Why?
|
| Professional Role | 1 | 2013 | 80 | 0.030 |
Why?
|
| Middle Aged | 2 | 2008 | 21119 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3256 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2077 | 0.020 |
Why?
|
| Abscess | 1 | 2005 | 37 | 0.020 |
Why?
|
| Thoracic Wall | 1 | 2005 | 20 | 0.020 |
Why?
|
| Methods | 1 | 1984 | 156 | 0.020 |
Why?
|
| Intubation | 1 | 1981 | 20 | 0.010 |
Why?
|
| Caprylates | 1 | 1981 | 32 | 0.010 |
Why?
|
| Solvents | 1 | 1981 | 108 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1995 | 166 | 0.010 |
Why?
|
| Liver | 2 | 1971 | 1118 | 0.010 |
Why?
|
| Dogs | 1 | 1995 | 490 | 0.010 |
Why?
|
| Bile Acids and Salts | 2 | 1971 | 19 | 0.010 |
Why?
|
| Acute Disease | 1 | 1995 | 658 | 0.010 |
Why?
|
| Bile | 1 | 1971 | 35 | 0.010 |
Why?
|
| Intestine, Small | 1 | 1971 | 89 | 0.010 |
Why?
|
| Lipid Metabolism | 1 | 1971 | 186 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1970 | 219 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1995 | 2550 | 0.000 |
Why?
|
| Animals | 3 | 1995 | 20877 | 0.000 |
Why?
|
| Haplorhini | 2 | 1971 | 44 | 0.000 |
Why?
|
| Secretory Rate | 1 | 1971 | 11 | 0.000 |
Why?
|
| Phosphatidylcholines | 1 | 1971 | 38 | 0.000 |
Why?
|
| Solubility | 1 | 1971 | 134 | 0.000 |
Why?
|
| Phospholipids | 1 | 1971 | 108 | 0.000 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 1970 | 9 | 0.000 |
Why?
|
| Ileum | 1 | 1970 | 28 | 0.000 |
Why?
|
| Intestinal Absorption | 1 | 1970 | 41 | 0.000 |
Why?
|
| Cholesterol | 1 | 1971 | 331 | 0.000 |
Why?
|
| Feces | 1 | 1970 | 88 | 0.000 |
Why?
|
| Lipids | 1 | 1970 | 298 | 0.000 |
Why?
|
| Models, Biological | 1 | 1971 | 981 | 0.000 |
Why?
|